Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02500199
Title Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hengrui Therapeutics, Inc.

lung non-small cell carcinoma

Her2-receptor positive breast cancer

Advanced Solid Tumor

stomach cancer



Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.